Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 2/20 | 0.55 |
| ▸ | CES1 | P23141 | 2/20 | 0.55 |
| ▸ | SNCA | P37840 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.48 |
| ▸ | FEN1 | P39748 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6420439 | 0.86 | CES2 (0.52) | POLBAPEX1CES2CES1SNCA | |
| SCHEMBL6419670 | 0.86 | POLB (0.56) | POLBAPEX1CES2CES1ALOX5AP | |
| SCHEMBL6433698 | 0.85 | CES2 (0.50) | CES2CES1SNCAL3MBTL1RAB9A | |
| SCHEMBL4599072 | 0.84 | POLB (0.50) | POLBAPEX1CES2CES1ALOX5AP | |
| SCHEMBL12121090 | 0.84 | POLB (0.54) | POLBAPEX1ALOX5APFEN1KDM4E | |
| SCHEMBL6416783 | 0.83 | CES2 (0.49) | POLBAPEX1CES2CES1SNCA | |
| SCHEMBL6419870 | 0.83 | CES2 (0.49) | CES2CES1SNCAL3MBTL1RAB9A | |
| SCHEMBL6418339 | 0.83 | KDM4E (0.51) | CES2CES1SNCAL3MBTL1RAB9A | |
| SCHEMBL6416032 | 0.83 | CES2 (0.49) | POLBAPEX1CES2CES1SNCA | |
| SCHEMBL6419694 | 0.83 | CNR2 (0.54) | CES2CES1SNCAL3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936736-B2 | Amide derivative | SUMITOMO MANUFACTURING COMPANY LIMITED (JP) | 2005-08-30 | — | — | US | claimed |
| EP-1034783-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS | SUMITOMO PHARMA (JP) | 2004-12-15 | — | — | EP | claimed |
| US-20020147204-A1 | Amide derivative | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2002-10-10 | — | — | US | claimed |
| US-6384033-B1 | DRUGS FOR VISION DEFECTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-05-07 | — | — | US | claimed |
| EP-1034783-A1 | AMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | claimed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20160168185-A1 | NON-RIBOSE CONTAINING INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L FOR CANCER TREATMENT | BAYLOR COLLEGE OF MEDICINE (US) | 2016-06-16 | — | — | US | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-6936736-B2 | Amide derivative | SUMITOMO MANUFACTURING COMPANY LIMITED (JP) | 2005-08-30 | — | — | US | disclosed |
| EP-1034783-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS | SUMITOMO PHARMA (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-20020147204-A1 | Amide derivative | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2002-10-10 | — | — | US | disclosed |
| US-6384033-B1 | DRUGS FOR VISION DEFECTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-05-07 | — | — | US | disclosed |
| JP-2000344752-A | EYE DROP | SUMITOMO PHARMACEUT CO LTD | 2000-12-12 | — | — | JP | disclosed |
| EP-1034783-A1 | AMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168185-A1 | NON-RIBOSE CONTAINING INHIBITORS OF HISTONE METHYLTRANSFERASE DOT1L FOR CANCER TREATMENT | DOT1L, CARM1, NSD1 | POLB 1987/4885APEX1 665/4885CES2 977/4885 |
| US-20020147204-A1 | Amide derivative | ALDH1A2, NR1H2, HDAC3 | POLB 3216/4885APEX1 1777/4885CES2 3713/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | POLB 4626/4885APEX1 3486/4885CES2 2835/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | POLB 4812/4885APEX1 4589/4885CES2 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.